Extend IP terms for pharma, says report on new drugs
Policy makers should consider extending the term of IP protection offered to pharmaceutical products to encourage more research into new drugs, a new report has recommended
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: